Why the study?
Limited data exist regarding the prognostic value of incorporating resting cardiac power-to-left ventricular mass and E/e' ratio in patients with HFpEF.
Does incorporating resting cardiac power-to-left ventricular mass and E/e' ratio predict prognosis in patients with HFpEF?
Does incorporating resting cardiac power-to-left ventricular mass and E/e' ratio predict prognosis in patients with HFpEF?
Answers are grounded in this paper and cite their sources.
Incorporating resting cardiac power-to-left ventricular mass and E/e' ratio provides powerful prognostic value for risk stratification in patients with HFpEF.
Background: Cardiac power-to-left ventricular mass (power/mass) is an index reflecting the muscular hydraulic pump capability of the heart, and the E/e' ratio is a specific indicator for identifying increased left ventricular filling pressure. Limited data exist regarding the prognostic value of incorporating power/mass and E/e' ratio in heart failure with preserved ejection fraction (HFpEF). Materials and methods: In total, 475 patients with HFpEF from the Treatment of Preserved Cardiac Function Heart Failure with an Aldosterone Antagonist (TOPCAT) trial with complete baseline echocardiography data were included in our analysis. Patients were categorized into four groups according to power/mass and E/e' ratio. The risk of outcomes was examined using Cox proportional hazards models and competing risk models. Conclusion: In patients with HFpEF, an echo-derived integrated approach incorporating resting power/mass and E/e' ratio remained to be a powerful prognosis predictor and may be useful to risk-stratify patients with this heterogeneous syndrome. Clinical Trial Registration: [https://clinicaltrials.gov], identifier [NCT00094302].
No takes yet. Share an insight, caveat, or question.
Chen et al. (2022) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: